2013
Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.
Petrylak D, Kantoff P, Mega A, Vogelzang N, Stephenson J, Fleming M, Stambler N, Petrini M, Huang K, Israel R. Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane. Journal Of Clinical Oncology 2013, 31: 119-119. DOI: 10.1200/jco.2013.31.6_suppl.119.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerProstate-specific membrane antigenMonomethyl auristatin EFree MMAEProstate cancer cellsProgressive metastatic castration-resistant prostate cancerDose levelsPhase 1 dose-escalation studyLiver function test elevationsCastration-resistant prostate cancerTaxane-containing chemotherapyAntitumor activityDose-escalation studyPhase 2 trialPhase I trialCancer cellsClinical disease progressionHighest dose levelSpecific membrane antigenECOG statusLFT abnormalitiesPrior docetaxelAdverse eventsEscalation studyI trial
2012
Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.
Mega A, Petrylak D, Kantoff P, Stephenson J, Vogelzang N, Dreicer R, Shore N, Stambler N, Carpenito J, D'Ambrosio P, Israel R. Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane. Journal Of Clinical Oncology 2012, 30: 4662-4662. DOI: 10.1200/jco.2012.30.15_suppl.4662.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerMonomethyl auristatin EHighest dose levelFree MMAEProstate cancer cellsDose levelsAdverse eventsProgressive metastatic castration-resistant prostate cancerPhase 1 dose-escalation studyCastration-resistant prostate cancerTumor cellsHigh-dose cohortTaxane-containing chemotherapyAntitumor activityCommon laboratory abnormalitiesDose-escalation studyLiver function testsPhase I trialCancer cellsClinical disease progressionDose cohortsECOG statusEscalation studyLaboratory abnormalitiesDose escalationProstate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in men with prostate cancer previously treated with taxane.
Petrylak D, Kantoff P, Mega A, Dreicer R, Frank R, Shore N, Morris S, Olson W, Israel R. Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in men with prostate cancer previously treated with taxane. Journal Of Clinical Oncology 2012, 30: 107-107. DOI: 10.1200/jco.2012.30.5_suppl.107.Peer-Reviewed Original ResearchMonomethyl auristatin EFree MMAEProstate cancer cellsAdverse eventsProstate cancerMetastatic castration-resistant prostate cancerPhase 1 dose-escalation studyCastration-resistant prostate cancerTumor cellsHigh-dose cohortTaxane-containing regimenAntitumor activityCommon laboratory abnormalitiesDose-escalation studyPhase I trialCancer cellsClinical disease progressionHighest dose levelBone painDose cohortsECOG statusEscalation studyLaboratory abnormalitiesI trialThird doses
2011
Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer.
Petrylak D, Kantoff P, Rotshteyn Y, Israel R, Olson W, Ramakrishna T, Morris S. Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer. Journal Of Clinical Oncology 2011, 29: 158-158. DOI: 10.1200/jco.2011.29.7_suppl.158.Peer-Reviewed Original ResearchMonomethyl auristatin EFree MMAEProstate cancer cellsProstate cancerRefractory metastatic prostate cancerDose-proportional PKTaxane-containing regimenCommon laboratory abnormalitiesDose-proportional mannerPhase I trialCancer cellsClinical disease progressionMetastatic prostate cancerOngoing phase IEnzyme-linked immunosorbent assay (ELISA) methodPotential clinical utilityImmunosorbent assay (ELISA) methodECOG statusAdverse eventsEscalation studyLaboratory abnormalitiesI trialThird dosesAntibody therapyLiquid chromatography/mass spectrometry/mass spectrometry method